Bristol Myers Squibb Executive Says Eliquis Q4 Sales to Be Affected by Europe LOE
A Bristol Myers Squibb executive said Eliquis sales in Q4 will be impacted by the upcoming loss of exclusivity in Europe.
Related stories
Asian Stocks Slide as Tech Selloff Intensifies
Asian stock markets declined on Friday, mirroring losses on Wall Street as technology and artificial intelligence shares came under renewed selling pressure following disappointing
H impact | EARNINGS | Oct 30, 2026, 01:09 AM UTC
OMG Group Reports Q1 FY27 Net Sales of A$1.92M
M impact | EARNINGS | Oct 30, 2026, 01:07 AM UTC
Robinhood Crypto Revenue Falls 55% as Prediction Markets Support Growth
Robinhood reported third-quarter 2026 results on October 27, with total net revenue of about $1.42 billion, up 12% year over year. Crypto revenue fell 55%, while prediction markets
M impact | EARNINGS | Oct 30, 2026, 01:06 AM UTC
Shionogi Revises 2026/27 Group Operating Forecast
Shionogi raised its 2026/27 group operating profit forecast by 4.5%.
M impact | EARNINGS | Oct 30, 2026, 01:00 AM UTC
Yokorei Revises 2025/26 Parent Recurring Profit Forecast
Yokorei revised its 2025/26 parent recurring profit forecast.
L impact | EARNINGS | Oct 30, 2026, 01:00 AM UTC
Yokorei Revises 2025/26 Parent Net Forecast to Loss
Yokorei revised its 2025/26 parent net forecast from profit to loss.
M impact | EARNINGS | Oct 30, 2026, 01:00 AM UTC